Alterity Therapeutics Ltd 6-K, filed Oct 16, 2020
Alterity Therapeutics Ltd (ATHE)
About this 6-K
Alterity Therapeutics Ltd filed this 6-K on October 16, 2020.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT
OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of October 2020
Alterity Therapeutics Limited
(Name of Registrant)
Level 3, 460 Bourke Street, Melbourne, VIC 3000, Australia
(Address of Principal Executive Office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): __
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): __
Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes ☐ No ☒
If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82- _____
This Form 6-K is being incorporated by reference into our Registration Statement on Form S-8 (Files No. 333-248980 and 333-228671) and our Registration Statements on Form F-3 (Files No. 333-249311 and 333-231417).
Alterity Therapeutics Limited
| 6-K | Items | |
| 99.1 | Proposed issue of Securities - ATH | |
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| ALTERITY THERAPEUTICS LIMITED | ||
| (Registrant) | ||
| By: | /s/ Geoffrey Kempler | |
| Geoffrey Kempler, | ||
| Executive Chairman | ||
October 16, 2020
2
Exhibit 99.1
 |
Proposed issue of securities |
Announcement Summary
Entity name
ALTERITY THERAPEUTICS LIMITED
Announcement Type
New announcement
Date of this announcement
Friday October 16, 2020
The Proposed issue is:
þ A placement or other type of issue
Total number of +securities proposed to be issued for a placement or other type of issue
| Maximum Number of | ||||
| ASX +security code | +Security description | +securities to be issued | ||
| ATH | ORDINARY FULLY PAID | 271,251,007 |
Proposed +issue date
Friday October 23, 2020
Refer to next page for full details of the announcement
| Proposed issue of securities | 1 / 5 |
|
Proposed issue of securities |
Part 1 - Entity and announcement details
1.1 Name of +Entity
ALTERITY THERAPEUTICS LIMITED
We (the entity named above) give ASX the following information about a proposed issue of +securities and, if ASX agrees to +quote any of the +securities (including any rights) on a +deferred settlement basis, we agree to the matters set out in Appendix 3B of the ASX Listing Rules.
| 1.2 Registered Number Type | Registration Number |
| ABN | 37080699065 |
1.3 ASX issuer code
ATH
1.4 The announcement is
þ New announcement
1.5 Date of this announcement
Friday October 16, 2020
1.6 The Proposed issue is:
þ A placement or other type of issue
| Proposed issue of securities | 2 / 5 |
|
Proposed issue of securities |
Part 7 - Details of proposed placement or other issue
Part 7A - Conditions
7A.1 - Are any of the following approvals required for the placement or other type of issue?
| ● | +Security holder approval |
| ● | Court approval |
| ● | Lodgement of court order with +ASIC |
| ● | ACCC approval |
| ● | FIRB approval |
| ● | Another approval/condition external to the entity |
þ No
Part 7B - Issue details
| Is the proposed security a ‘New class’ (+securities in a class that is not yet quoted or recorded by ASX) or an ‘Existing class’ (additional securities in a class that is already quoted or recorded by ASX)? | Will the proposed issue of this +security include an offer of attaching +securities? þ No |
|
| þ Existing class |
Details of +securities proposed to be issued
ASX +security code and description
ATH : ORDINARY FULLY PAID
Number of +securities proposed to be issued
271,251,007
Offer price details
Are the +securities proposed to be issued being issued for a cash consideration?
þ Yes
| In what currency is the cash consideration being paid? | What is the issue price per +security? | |
| AUD - Australian Dollar | AUD 0.03700 |
Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class?
þ Yes
| Proposed issue of securities | 3 / 5 |
|
Proposed issue of securities |
Part 7C - Timetable
7C.1 Proposed +issue date
Friday October 23, 2020
Part 7D - Listing Rule requirements
7D.1 Has the entity obtained, or is it obtaining, +security holder approval for the entire issue under listing rule 7.1?
þ No
7D.1b Are any of the +securities proposed to be issued without +security holder approval using the entity's 15% placement capacity under listing rule 7.1?
þ Yes
7D.1b ( i ) How many +securities are proposed to be issued without security holder approval using the entity's 15% placement capacity under listing rule 7.1?
| (ASX:ATH) 162,750,604 |
7D.1c Are any of the +securities proposed to be issued without +security holder approval using the entity's additional 10% placement capacity under listing rule 7.1A (if applicable)?
þ Yes
7D.1c ( i ) How many +securities are proposed to be issued without +security holder approval using the entity's additional 10% placement capacity under listing rule 7.1A?
| (ASX:ATH) 108,500,403 |
7D.1c ( ii ) Please explain why the entity has chosen to do a placement rather than a +pro rata issue or an offer under a +security purchase plan in which existing ordinary +security holders would have been eligible to participate
| Due to the costs and timing benefits of completing the placement. |
7D.2 Is a party referred to in listing rule 10.11 participating in the proposed issue?
þ No
7D.3 Will any of the +securities to be issued be +restricted securities for the purposes of the listing rules?
þ No
7D.4 Will any of the +securities to be issued be subject to +voluntary escrow?
þ No
| Proposed issue of securities | 4 / 5 |
|
Proposed issue of securities |
Part 7E - Fees and expenses
7E.1 Will there be a lead manager or broker to the proposed issue?
þ Yes
7E.1a Who is the lead manager/broker?
| MST Financial Services Pty. Ltd. |
7E.1b What fee, commission or other consideration is payable to them for acting as lead manager/broker?
| 5% of the placement |
7E.2 Is the proposed issue to be underwritten?
þ No
7E.4 Details of any other material fees or costs to be incurred by the entity in connection with the proposed issue
Part 7F - Further Information
7F.01 The purpose(s) for which the entity is issuing the securities
| To further research and development activities, provide on-going working capital as disclosed in the announcement dated 16 October 2020. |
7F.1 Will the entity be changing its dividend/distribution policy if the proposed issue proceeds?
þ No
7F.2 Any other information the entity wishes to provide about the proposed issue
| Proposed issue of securities | 5 / 5 |